Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P200032/S003

Occlutech ASD Occluder; Occlutech Pistol Pusher (OPP); Occlutech ASD Occluder Procedure Pack

Occlutech Holding AG · Decision date Nov 24, 2025

FDA DECISIONP200032/S003

What did the FDA approve?

FDA records P200032/S003 as a supplement to PMA P200032, with the supplement type “Real-Time Process”. The recorded decision is approval, dated Nov 24, 2025.

FDA approval order statement

Approval for a change in the minimum recommended French sizes of the Occlutech Delivery Set III (ODS III) compatible with most Occlutech ASD Occluder sizes
Regulatory pathway
PMA supplement
Supplement type
Real-Time Process
Clinical specialty
Cardiovascular
Decision date
Nov 24, 2025
FDA change category
Labeling Change - Indications/instructions/shelf life/tradename

FDA source record

Regulatory record facts

Identifier
P200032/S003
Regulatory pathway
PMA supplement
Product code
OZG
Decision code
APPR
Decision date
Nov 24, 2025
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Transcatheter septal occluder (atrial).

Product code
OZG
FDA device class
3

Review the original FDA PMA listing for the original approval scope and linked supplements.

FDA decision timeline

  1. P200032/S003 received

    Application receipt date recorded by FDA.

  2. P200032/S003 · FDA decision

    Real-Time Process

  3. P200032/S004 · Related supplement

    Occlutech ASD Occluder; Occlutech Pistol Pusher (OPP); Occlutech ASD Occluder Procedure Pack

  4. P200032/S005 · Related supplement

    Occlutech Pistol Pusher

  5. P200032/S006 · Related supplement

    Occlutech ASD Occluder and Occlutech Pistol Pusher

Timeline entries are records held by MedtechLedger for P200032. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P200032

Product / regulatory recordCompanyPathwayDecision dateSource
Occlutech Holding AGPMA supplementDec 18, 2025FDA
Occlutech Holding AGPMA supplementMay 11, 2026FDA
Occlutech Holding AGPMA supplementJun 5, 2026FDA

Explore the linked device profile

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

FDA describes the real-time supplement process as a review route for minor changes to a device, including certain design, software, sterilization or labeling changes.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Occlutech Holding AG

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
Feldstrasse 22, Schaffhausen, 8200

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records